Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR)(CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-Containing Line
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus
cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as
treatment in patients with small-cell lung cancer (SCLC) who failed one prior
platinum-containing line to determine a difference in progression-free survival (PFS) by an
Independent Review Committee (IRC) between lurbinectedin (PM01183)/doxorubicin (DOX) and the
control arm (CAV) or topotecan and to analyze the median overall survival (OS) and mid- and
long-term overall survival (OS at 12, 18 and 24 months).
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.